Safety and tolerability of inhaled treprostinil with phosphodiesterase-5 inhibitors in patients with pulmonary hypertension due to interstitial lung disease - Milan 2023

Pulmonary hypertension in lung disease and hypoxia

Chair(s): Deimante Hoppenot, Da-Hee Park

Session type: Poster session

Safety and tolerability of inhaled treprostinil with phosphodiesterase-5 inhibitors in patients with pulmonary hypertension due to interstitial lung disease

David Zisman

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Prediction of survival in patients with pulmonary hypertension associated with interstitial lung disease treated with pulmonary vasodilators

Jun Fukihara

Poster

Abstract

CircPMS1 promotes proliferation of pulmonary artery smooth muscle cells, pulmonary microvascular endothelial cells, and pericytes under hypoxia

Xiaoyi Hu

Poster

Abstract

Multi-institutional Development and External Validation of Nomograms for the Prediction of Diagnosis and Survival in COPD with Severe Pulmonary Hypertension

Yuqin Chen

Abstract

Predicting Pulmonary Pharmacokinetics of Inhaled Liposomal Treprostinil (L606) and Treprostinil Solution in Healthy Adult

Pei Kan

Poster

Abstract

Use of pulmonary vasodilator therapy in anti-synthetase syndrome-associated pulmonary hypertension

Thomas Mason

Poster

Abstract

Improved survival after treatment with pulmonary vasodilator therapies in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry

Laura Price

Poster

Abstract

The Effect of Subcutaneous Treprostinil on Pulmonary Hypertension Associated with Interstitial Lung Disease

Roela Sadushi-kolici

Poster

Abstract

Reduced pulmonary vascular density in severe pulmonary hypertension associated with chronic lung disease

Agustin Roberto Garcia

Poster

Abstract

Pulmonary hypertension in patients with Progressive Fibrosing Interstitial Lung disease(PF-ILD)referred for Lung transplantation:Retrospective study from India.

Manjunath M N

Poster

Abstract

Severity of pulmonary hypertension in lung disease: impact of the 2022 guidelines on the REHAR registry population

Diego Rodriguez Chiaradia

Poster

Abstract

Correlations between lung injury and peripheral vascular manifestations in patients with systemic sclerosis: a preliminary study

Barbara Ruaro

Poster

Abstract

An open-label, pharmacodynamic trial investigating vascular effects of the angiotensin II type 2 receptor (AT2R) agonist (ATRAG) C21

Rohit Batta

Poster

Abstract

Artificial intelligence to detect pulmonary hypertension in idiopathic pulmonary fibrosis: Study design

Laura Price

Poster

Abstract

Pulmonary Hypertension International Survey of Health Impacts (PHISH): a global patient questionnaire

Joseph Newman

Poster

Abstract

Artificial Intelligence and Computed Tomography to improve quantification and prognostication of lung disease in precapillary pulmonary hypertension

Krit Dwivedi

Poster

Abstract

Safety and tolerability of inhaled treprostinil with phosphodiesterase-5 inhibitors in patients with pulmonary hypertension due to interstitial lung disease

David Zisman

Poster

Abstract

Effect of Targeted Pulmonary Arterial Hypertension Therapy on Arterial Oxygenation in Patients With Pulmonary Hypertension Associated With Lung Disease: A Systematic Review and Meta-analysis

Rodrigo Torres Castro

Poster

Abstract

PH-ILD management and unmet need in Europe: a clinician survey

Luke Howard

Poster

Abstract

PH-ILD patient characteristics and burden of disease in Europe: a clinician survey

David Montani

Poster

Abstract

What role does the NLRP3 Inflammasome play in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SScPAH)?

Jennifer Rossdale

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}